Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will host its third quarter 2021 earnings call on November 9, 2021, at 8:00 a.m. ET, where it will report financial results for the quarter ending September 30, 2021. The call will highlight recent achievements and upcoming milestones. Investors can access the call via phone or through the company's website. Biohaven focuses on innovative treatments for neurological and neuropsychiatric conditions, with notable products including FDA-approved NURTEC ODT for migraine management.
- Biohaven's focus on innovative therapies for neurological diseases.
- Recent accomplishments to be highlighted in the upcoming earnings call.
- FDA-approved NURTEC ODT broadens Biohaven's market presence.
- None.
NEW HAVEN, Conn., Nov. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming third quarter 2021 earnings call and webcast, reporting financial results for the quarter ended September 30, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones, on Tuesday November 9, 2021 at 8:00 a.m. ET.
To access the call, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast and accompanying slide presentation can be accessed through the "Investors" section of Biohaven's website at www.biohavenpharma.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the call will be made available for two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (domestic) or 201-612-7415 (international) with conference ID 13723890. An archived webcast will be available on Biohaven's website.
About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation™ portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.
NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.
Neuroinnovation is a trademark of Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-to-report-third-quarter-2021-financial-results-and-recent-business-developments-on-november-9-2021-301416388.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.
FAQ
When is Biohaven's third quarter 2021 earnings call scheduled?
What financial results will Biohaven disclose during its upcoming earnings call?
How can I access Biohaven's earnings call?
What is the focus of Biohaven's product portfolio?
What is NURTEC ODT?
